CP Reports
CP Insight
Current Agreements
CP Knowledge Centre
CP Consulting

New report

Provides comprehensive understanding and unprecedented access to the  clinical stage partnering agreements deals and agreements entered into by the worlds leading healthcare companies. More

 

Featured partnering deals

Big pharma, Pfizer gives $2 million to immunize Africa

September 22, 2014 : big pharma, grants, Pfizer

Big pharma,  Pfizer Foundation announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa. more »

Sobi and Biogen Idec sign a pharma deal for hemophilia

September 22, 2014 : big pharma, Biogen Idec, pharma deals, pharma licensing

Swedish Orphan Biovitrum has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s pharma deal with Biogen Idec. more »

 More partnering deals | all deals at Deal Monitor


Featured M&A deals

Big pharma, Merck will acquire Sigma-Aldrich for $17 billion

September 22, 2014 : acquisition, big pharma, M&A, Merck

Merck KGaA agreed to acquire Sigma-Aldrich for $17 billion in cash to expand in chemicals used in research labs and pharmaceutical manufacturing and reduce its dependence on drug development. more »

Denovo Biopharma has acquired enzastaurin from Eli Lilly

September 18, 2014 : acquisition, asset purchase, Eli Lilly, M&A

Denovo Biopharma has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. more »

 More M&A deals | all deals at Deal Monitor

Featured financing deals

Recipharm has gotten a loan financing for $210 million

September 22, 2014 : financing, financings

Recipharm has entered a new five-year SEK 1 500 million (approximately $210 million) loan financing with three of the largest banks in Scandinavia. more »

Icon gets $40 million through share repurchase financing

September 22, 2014 : financing, financings

Icon has completed a $40 million buyback financing of the Company’s ordinary shares through open market acquisitions at an average price of $49.87. more »

 More financing deals | all deals at Deal Monitor

Latest Dealtalk

Akorn to bid for an acquisition of UCB’s subsidiary

September 15, 2014 : acquisition, dealtalk, M&A

Akorn targets UCB’s subsidiary for acquisition for tax inversion.  more »

Orphan diseases partnering: A lucrative step for drug makers

September 2, 2014 : M&A, orphan diseases, partnering

By Shamini Thiagarajan

Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases. more »

 More dealtalk

Featured reports

 

Discovery Stage Partnering Terms and Agreements

Publication date: September 2014

Preclinical Stage Partnering Terms and Agreements

Publication date: September 2014

Co-development Terms and Agreements

Publication date: August 2014

Personalized Medicine in Oncology Partnering Terms and Agreements

Publication date: August 2014

Licensing Terms and Agreements

Publication date: August 2014

Diagnostic Imaging Partnering Terms and Agreements

Publication date: August 2014

Trends in Therapeutic Partnering

Publication date: August 2014

Cancer Monoclonal Antibody Terms and Agreements

Publication date: August 2014

Monoclonal Antibody Terms and Agreements

Publication date: August 2014

Co-promotion & Co-marketing Partnering Terms and Agreements

Publication date: July 2014

Drug Delivery Terms and Agreements

Publication date: July 2014

Vaccine Partnering Terms and Agreements

Publication date: July 2014

Distribution Partnering Terms and Agreements

Publication date: July 2014

Diagnostics Partnering Terms and Agreements

Publication date: July 2014

Pharma and Biotech M&A Trends 2009-2014

Publication date: July 2014

NEW: Therapy deal reports covering all major indications

Including partnering in oncology, cardiovascular, CNS, metabolic, dermatology, dental, infectives, immunologypsychiatry, genitourinary.....plus many others

View all reports

Scorecard

Current Partnering provides access to key deal metrics for all leading partnering, M&A and financings - plus big pharma partnering activity and R&D spend metrics.

Available scorecards:

Partnering

M&A

Financing

Top 50 pharma partnering

Top 50 biotech partnering

Top pharma R&D spend

Deal metrics - by stage of development, therapy area, industry sector

Print Friendly
bannerpng
RSS Feed Linked In Twitter

Latest Tweets

cpbannerad300x150new1gif
pharmavenue-datesjpg
biospain-banner-institucional-300x150gif